Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.

Objective: To evaluate the efficacy and tolerability of montelukast 20 mg in the prophylactic treatment of migraine.

Background: A previous small open-label study in migraine patients suggested prophylactic efficacy for montelukast, an antagonist of the cysteinyl leukotriene receptor that is used in the treatment of asthma. We sought to confirm these findings in a randomized controlled trial.